Research Analysts’ Recent Ratings Changes for Corcept Therapeutics (CORT)

A number of research firms have changed their ratings and price targets for Corcept Therapeutics (NASDAQ: CORT):

• 3/26/2026 – Corcept Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $100.00 to $110.00. They now have a “buy” rating on the stock.
• 3/26/2026 – Corcept Therapeutics was upgraded by Wolfe Research from “underperform” to “peer perform”.
• 3/25/2026 – Corcept Therapeutics was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/25/2026 – Corcept Therapeutics had its price target lowered by HC Wainwright from $67.00 to $60.00. They now have a “buy” rating on the stock.
• 2/20/2026 – Corcept Therapeutics had its price target lowered by HC Wainwright from $105.00 to $67.00. They now have a “buy” rating on the stock.

Insider Activity

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of the company’s stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $40.97, for a total transaction of $819,400.00. Following the completion of the sale, the insider directly owned 2,231 shares of the company’s stock, valued at approximately $91,404.07. This represents a 89.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Joseph K. Belanoff sold 26,198 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the completion of the transaction, the chief executive officer directly owned 2,918,326 shares in the company, valued at approximately $146,120,582.82. This trade represents a 0.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 86,198 shares of company stock valued at $3,668,569 over the last three months. Insiders own 20.50% of the company’s stock.

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.